Jesse Waggoner
Overview
Explore the profile of Jesse Waggoner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
364
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oshinowo O, Copeland R, Patel A, Shaver N, Fay M, Jeltuhin R, et al.
Nat Commun
. 2024 Nov;
15(1):10201.
PMID: 39587073
Altered mechanotransduction has been proposed as a putative mechanism for disease pathophysiology, yet evidence remains scarce. Here we introduce a concept we call single cell immuno-mechanical modulation, which links immunology,...
2.
Duvignaud A, Stoney R, Angelo K, Chen L, Cattaneo P, Motta L, et al.
J Travel Med
. 2024 Jul;
31(7).
PMID: 38951998
Background: Dengue is a leading cause of febrile illness among international travellers. We aimed to describe the epidemiology and clinical characteristics of imported dengue in returning travellers evaluated at GeoSentinel...
3.
Lin C, Page A, Lohsen S, Haider A, Waggoner J, Smith G, et al.
JAC Antimicrob Resist
. 2024 Mar;
6(2):dlae048.
PMID: 38515868
Background: Heteroresistance (HR), the presence of antibiotic-resistant subpopulations within a primary isogenic population, may be a potentially overlooked contributor to newer β-lactam/β-lactamase inhibitor (BL/BLI) treatment failure in carbapenem-resistant Enterobacterales (CRE)...
4.
Brown A, Miller C, Hamer D, Kozarsky P, Libman M, Huits R, et al.
MMWR Surveill Summ
. 2023 Jun;
72(7):1-22.
PMID: 37368820
Problem/condition: During 2012-2021, the volume of international travel reached record highs and lows. This period also was marked by the emergence or large outbreaks of multiple infectious diseases (e.g., Zika...
5.
Huits R, Angelo K, Amatya B, Barkati S, Barnett E, Bottieau E, et al.
Ann Intern Med
. 2023 Jun;
176(7):940-948.
PMID: 37335991
Background: Dengue virus is a flavivirus transmitted by mosquitoes and is an important cause of illness worldwide. Data on the severity of travel-associated dengue illness are limited. Objective: To describe...
6.
Shantha J, Fashina T, Stittleburg V, Randleman C, Ward L, Regueiro M, et al.
PLoS One
. 2022 Nov;
17(11):e0277301.
PMID: 36350841
Purpose: To assess hospitalized COVID-19 inpatients for the prevalence of retinopathy and tear film SARS-CoV-2 RNA, and associated risk factors for their detection. Methods: Hospitalized COVID-19 patients underwent dilated ophthalmic...
7.
Lane M, Walawender M, Webster A, Brownsword E, Ingersoll J, Miller C, et al.
Viruses
. 2021 Dec;
13(12).
PMID: 34960615
Evidence varies as to how far aerosols spread from individuals infected with SARS-CoV-2 in hospital rooms. We investigated the presence of aerosols containing SARS-CoV-2 inside of dedicated COVID-19 patient rooms....
8.
Gomes L, Jeewandara C, Jayadas T, Dissanayake O, Harvie M, Guruge D, et al.
J Virol Methods
. 2021 Nov;
300:114374.
PMID: 34822912
Background: Although active surveillance SARS-CoV-2 variants of concern (VOCs) is required for proper outbreak control measures, many lower income countries find it challenging to detect VOCs by carrying genomic sequencing...
9.
Lane M, Brownsword E, Babiker A, Ingersoll J, Waggoner J, Ayers M, et al.
Clin Infect Dis
. 2021 Jan;
73(7):e1790-e1794.
PMID: 33506256
Background: Previous research has shown that rooms of patients with coronavirus disease 2019 (COVID-19) present the potential for healthcare-associated transmission through aerosols containing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). However,...
10.
Hoang T, Pino M, Boddapati A, Viox E, Starke C, Upadhyay A, et al.
Cell
. 2020 Dec;
184(2):460-475.e21.
PMID: 33278358
SARS-CoV-2-induced hypercytokinemia and inflammation are critically associated with COVID-19 severity. Baricitinib, a clinically approved JAK1/JAK2 inhibitor, is currently being investigated in COVID-19 clinical trials. Here, we investigated the immunologic and...